Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 16;18(1):694.
doi: 10.1186/s13018-023-04182-w.

Analgesic efficacy of collagen peptide in knee osteoarthritis: a meta-analysis of randomized controlled trials

Chun-Ru Lin  1 , Sung Huang Laurent Tsai  2 , Ko-Yen Huang  3 , Po-An Tsai  1 , Hsuan Chou  4 , Shu-Hao Chang  5   6
Affiliations

Analgesic efficacy of collagen peptide in knee osteoarthritis: a meta-analysis of randomized controlled trials

Chun-Ru Lin et al. J Orthop Surg Res. .

Abstract

Background: The management of knee osteoarthritis involves various treatment strategies. It is important to explore alternative therapies that are both safe and effective. Collagen peptides have emerged as a potential intervention for knee osteoarthritis. This study aims to evaluate the analgesic effects and safety of collagen peptide in patients diagnosed with knee osteoarthritis.

Methods: We conducted a systematic literature search following the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Multiple databases including PubMed, Scopus, EMBASE, Web of Science, Cochrane, and ClinicalTrials.gov were searched for randomized controlled trials (RCTs) published up to 27 May 2023 that focused on the analgesic outcomes and adverse events associated with collagen peptides or hydrolyzed collagen in patients with osteoarthritis. We assessed the quality of the included studies and the strength of evidence using the Cochrane ROB 2.0 tool and Grading of Recommendations, Assessment, Development, and Evaluations.

Results: Four trials involving 507 patients with knee osteoarthritis were included and analyzed using the random-effects model. All these trials were considered to have a high risk of bias. Our results revealed a significant difference in pain relief between the collagen peptide group and the placebo group in patients with knee osteoarthritis (standardized mean difference: - 0.58; 95% CI - 0.98, - 0.18, p = 0.004; I2: 68%; quality of evidence: moderate). However, there was no significant difference in the risk of adverse events between collagen peptide and placebo (odds ratio: 1.66; 95% CI 0.99, 2.78, p = 0.05; I2: 0%; quality of evidence: very low).

Conclusions: Our findings demonstrate significant pain relief in patients with knee osteoarthritis who received collagen peptides compared to those who received placebo. In addition, the risk of adverse events did not differ significantly between the collagen peptide group and the placebo group. However, due to potential biases and limitations, well-designed randomized controlled trials are needed to validate and confirm these findings.

Keywords: Adverse events; Collagen peptide; Knee osteoarthritis; Osteoarthritis; Pain.

PubMed Disclaimer

Conflict of interest statement

Financial, commercial, or other relationships were absent in this research. There was no conflict of interest in this research.

Figures

Fig. 1
Fig. 1
Flow of identification, screening, eligibility, and inclusion
Fig. 2
Fig. 2
ROB2, risk of bias assessment of the included studies, and the summary of domains
Fig. 3
Fig. 3
The summary of domains of the risk of bias
Fig. 4
Fig. 4
Forest plot demonstrating overall pain scores comparing between collagen peptides and placebo. Better pain control is shown if favor collagen peptides or placebo
Fig. 5
Fig. 5
Forest plot demonstrating overall adverse events between collagen peptides and placebo. Lower adverse event is shown if favor collagen peptides or placebo
Fig. 6
Fig. 6
Post hoc analysis of pain scores including data in all different conditions in Trč 2011 between collagen peptide and placebo. Better pain control is shown if favor collagen peptides or placebo. Trč 2011: VAS measured in pain right now. Trč 2011*: VAS measured of typical or average pain Trč 2011**: VAS measured of pain level at its best. Trč 2011***: VAS measured of pain level at its worst
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Hsu H, Siwiec RM. Knee osteoarthritis. Treasure Island (FL): StatPearls Publishing; 2022. - PubMed
    1. Fang H, Huang L, Welch I, Norley C, Holdsworth DW, Beier F, et al. Early changes of articular cartilage and subchondral bone in the DMM mouse model of osteoarthritis. Sci Rep. 2018;8:2855. doi: 10.1038/s41598-018-21184-5. - DOI - PMC - PubMed
    1. Bastick AN, Runhaar J, Belo JN, Bierma-Zeinstra SMA. Prognostic factors for progression of clinical osteoarthritis of the knee: a systematic review of observational studies. Arthritis Res Ther. 2015;17:152. doi: 10.1186/s13075-015-0670-x. - DOI - PMC - PubMed
    1. Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Clin Geriatr Med. 2010;26:355–369. doi: 10.1016/j.cger.2010.03.001. - DOI - PMC - PubMed
    1. Losina E, Paltiel AD, Weinstein AM, Yelin E, Hunter DJ, Chen SP, et al. Lifetime medical costs of knee osteoarthritis management in the United States: impact of extending indications for total knee arthroplasty. Arthritis Care Res. 2015;67:203–215. doi: 10.1002/acr.22412. - DOI - PMC - PubMed

LinkOut - more resources